Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The combination therapy effectively treats infertility in PCOS without major side effects.

Certain hormone treatments can increase SBP levels and help with mild body hair growth.

Baricitinib is effective as a treatment for severe hair loss.

Lifestyle changes are more effective than metformin in reducing type 2 diabetes risk in women with PCOS.

Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.

Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.

The document's conclusion cannot be provided because the content is not available.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.

The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.

Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Cyproterone acetate is effective for treating hirsutism and acne in women by blocking androgens in the skin and also works as a contraceptive.

PCOS is a common disorder in women causing hormonal imbalance and fertility issues, often managed with lifestyle changes and medication.

Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.

Newer contraceptives with less androgenic progestins may reduce female hair loss.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

The compound improved hair growth and reduced hair loss.

The treatment slightly increased hair growth and was safe for most women.

Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.